Please login to the form below

Not currently logged in
Email:
Password:

CAR-T

This page shows the latest CAR-T news and features for those working in and with pharma, biotech and healthcare.

Gracell reports impressive data with one-day CAR-T for leukaemia

Gracell reports impressive data with one-day CAR-T for leukaemia

Takes fight to Novartis and Gilead. Gracell Biotechnologies has thrown down a gauntlet to Novartis and Gilead Sciences with a CD19-targeting CAR-T for B-cell acute lymphoblastic leukaemia ... The CAR-T samples for each of the 26 patients enrolled into

Latest news

  • Novartis’ CAR-T Kymriah scores SMC approval Novartis’ CAR-T Kymriah scores SMC approval

    The SMC approved the CAR-T therapy for use in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), who have not responded to two or more prior ... Novartis’ CAR-T rival from Gilead, Yescarta, has a UK list price of nearly

  • Celgene boosts IO presence with Immatics deal Celgene boosts IO presence with Immatics deal

    CAR-T cell therapies, the most clinically established form of ACT, can recognise only the specific antigens on the surface of cancer cells. ... It also  acquired CAR-T specialist Juno therapeutics for $9bn in 2018, giving it rights to lead CAR-T

  • GSK preps filings for BCMA-targeting multiple myeloma drug GSK preps filings for BCMA-targeting multiple myeloma drug

    classes. GSK is only revealing the top-line win and hasn’t provided detail of the data, but the study seems to back up an earlier open-label trial called  ... GSK2857916 is one of a slew of BCMA-targeting therapies coming through the biopharma

  • BMS buoyed by FDA approval of Celgene’s myelofibrosis drug BMS buoyed by FDA approval of Celgene’s myelofibrosis drug

    Fedratinib was one of the late-stage development programmes highlighted by BMS when the merger was announced in January, although others – such as multiple sclerosis drug ozanimod and CAR-T cancer

  • Bayer takes control of BlueRock stem cell joint venture Bayer takes control of BlueRock stem cell joint venture

    BlueRock is also developing iPSCs that differentiate into microglia, oligodendrocytes and eneic neurons for neurology applications, cardiomyocytes for heart failure, as well as macrophages and T regulatory cells for immunology applications

More from news
Approximately 40 fully matching, plus 138 partially matching documents found.

Latest Intelligence

  • The dawn of a new era in medical education The dawn of a new era in medical education

    Innovation is not without its challenges. Let’s take haematology as our case study; there has been a flurry of revolutionary cell therapies to treat blood cancers, including CAR-T therapies.

  • Biotech profile: Tom Evans, CEO, Vaccitech.

    We won’t compete directly with big vaccine companies, but may partner with them to support late phase product development and commercialisation. ... This is hard to know. The value of T cell approaches, especially CD8 T cells, has been shown by the

  • 25 Women Leaders in UK Healthcare (part 2) 25 Women Leaders in UK Healthcare (part 2)

    It has brought to market not one but two groundbreaking drugs in hepatitis C, Harvoni, and in diffuse large B cell lymphoma, Yescarta, one of the first CAR-T therapies to ... This is demonstrated in Gilead securing two truly groundbreaking partnerships

  • Bluebird: on a mission to ‘recode’ the DNA of healthcare Bluebird: on a mission to ‘recode’ the DNA of healthcare

    This is informed by the experience of CAR-T cell therapies, where Novartis’ Kymriah – the first ever CAR-T approved in 2017 – looks set to remain a loss-leader for many ... Its most important pipeline candidate, however, is the multiple myeloma

  • “Brexit has been a catalyst for UK clinical research... it’s turbocharged change” “Brexit has been a catalyst for UK clinical research... it’s turbocharged change”

    He said it remains a frustration that international perceptions of UK clinical research haven’t kept pace with that change in performance on the ground. ... can make it on to the market early – agreements on the two CAR-T drugs, Novartis’ Kymriah

More from intelligence
Approximately 0 fully matching, plus 49 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 2 fully matching, plus 9 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

Article: Like, Like, Like: Harnessing the power of social media insights
...
Its Know Your Numbers week
Do you know yours?...
What is changing in mental health and dementia care?
Paul Midgley, of Wilmington Healthcare, takes a look at the NHS Long Term Plan's bid to transform mental health and dementia services...

Infographics